Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...

Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with ...

The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH. The FDA has approved the Optilume BPH Catheter System for the treatment of lower ...

Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.

Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT. Using PSMA-PET imaging and ...

This digital series features articles and videos with insights and expert viewpoints on PSMA-PET and the evolving imaging paradigm that is revolutionizing the diagnosis and treatment of patients with ...

Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Overall, a ...

Lawsuit was resolved at mediation for $3,500,000. A 65-year-old man presented to his urologist with symptoms of an enlarged prostate. He agreed to allow the urologist to perform a transurethral ...

Pocenbrodib targets CREBBP/EP300 proteins, inhibiting cancer cell growth in mCRPC, with promising results from the COURAGE study. The trial includes monotherapy and combination therapy arms, focusing ...

Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...

The deep PSA responses with the darolutamide regimen were found to be correlated with improved overall survival and a prolonged time to PSA progression. The addition of darolutamide (Nubeqa) to ...